Previous 10 | Next 10 |
MALVERN, Pa., April 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has adjourned its 2021 Annual Meeting of Shareholders (the “Annual Meeting&...
MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved an inducement grant of stock options...
The following slide deck was published by Baudax Bio, Inc. in conjunction with this event. For further details see: Baudax Bio (BXRX) Investor Presentation - Slideshow
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will participate in a fireside chat at the virtual Oppenheim...
BXRX is a currently discounted analgesia company that suffered from reduced demand due to COVID-19 pressure on elective surgeries. The company currently has an FDA-approved post-op analgesic that is favored by anesthesiologists, as well as a focused pipeline that could push it to the ...
Baudax Bio (BXRX) appointed Mr. Richard S. Casten as Chief Financial Officer to succeed Ryan D. Lake, who is transitioning to full time Chief Financial Officer for Recro.Mr. Casten, most recently served as Vice President of Finance, Controller and Treasurer at Lupin Pharma...
Companhia Brasileira de Distribuicao (CBD) -76%.Soleno Therapeutics (SLNO) -26% after providing update on DCCR for the treatment of Prader-Willi syndromeSify Technologies (SIFY) -15%.Luokung Technology (LKCO) -15% after receipt of Nasdaq notification letter and a request for emergen...
MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible f...
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Gl...
Baudax Bio recently reported their Q4/2020 earnings that revealed a huge miss on EPS and revenue. The COVID-19 headwinds continue to restrict Anjeso's ability to get off the launch pad. Despite the disappointing start, the company has several commercial highlights that investors shoul...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023